Name: Urinary Tract Cancer Treatment Market Size Share & Forecast 2023-2030
Creator: DataM Intelligence
Published: Fri Oct 06 2023 16:06:43 GMT+0530 (India Standard Time)
License: https://www.datamintelligence.com/terms-conditions

Urinary Tract Cancer Treatment Market Size Share & Forecast 2023-2030

Urinary Tract Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Urinary Tract Cancer Treatment Market is segmented By Cancer Type&nbsp;(Bladder Cancer, Urethral Cancer, Ureteric Cancer, Renal Pelvic Cancer), By Treatment Type&nbsp;(Immunotherapy, Chemotherapy), By Distribution Channel&nbsp;(Retail Pharmacy, Online Pharmacy, Hospital Pharmacy), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029.</h2>

<blockquote>
Urinary Tract Cancer Treatment Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of&nbsp; 18.4% during the forecast period (2022-2029).&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;
</blockquote>

The most prevalent type of cancer detected in the urethra, bladder, and renal pelvis is urinary tract cancer. The gold standard procedure for diagnosing bladder cancer is a cystoscopy. In macroscopic hematuria, another method, computed tomography (CT) urography, is employed to obtain pictures of the upper tract. The exact cause of urinary tract cancer is unknown; however, long-term indwelling bladder catheters, smoking, chronic inflammation of the urinary system, and exposure to carcinogenic substances are all established risk factors.

<h3>Urinary Tract Cancer Treatment Market Dynamics</h3>

Urinary tract cancer treatment market is growing due to an increase in the prevalence of urinary tract cancer, the elderly population, and the number of bladder cancer research institutes.

Increasing prevalance of bladder cancer will drive the market growth &nbsp;&nbsp;

Increased prevalence of bladder cancer, increased funding from private and government organizations for the construction of research centers, increased elderly population, and increased R&amp;D activities in the healthcare sector are all driving the worldwide urinary tract cancer market forward. Bladder cancer is the world&#39;s tenth most frequent cancer. According to the American Cancer Society, approximately 83,730 people in the United States will be diagnosed with bladder cancer in 2021. Furthermore, the bladder cancer research institutes, founded at the University of Birmingham in the United Kingdom, were sponsored with $1.18 million thanks to University investment and private donations. Furthermore, the rise in the geriatric population, which is more susceptible to bladder cancer, will propel the market forward throughout the projection period. Because the immune cells that combat cancer tissue in the bladder diminish with age, the elderly are more susceptible to urinary tract cancer. According to the American Society of Clinical Oncology (ASCO), over 90% of persons with bladder cancer will be over 55 in January 2021.

Furthermore, according to the American Cancer Society, bladder cancer can be caused by a combination of smoking and job exposure. For example, Merck, a leading global biopharmaceutical company, announced in August 2021 that Keytruda (pembrolizumab), used to treat Urothelial Carcinoma, has received FDA clearance in the United States. As a result, the market is expected to grow due to an increase in the number of approvals for the treatment of urinary tract cancer and an increase in sedentary lifestyles such as smoking and increased exposure to the chemical sector. Furthermore, there is a surge in the number of cancer research facilities and highly specialized urologists for cancer therapy.

Side effects caused by medications is likely to hamper the market growth&nbsp; 

However, the market is stifled by the risks connected with the usage of medications used to treat urinary tract cancer.

<h3>COVID-19 Impact Analysis</h3>

The outbreak of the COVID-19 pandemic has negatively impacted the global urinary tract cancer marketAlmost all hospitals and cancer centers have reduced their outpatient capacity and conducted a triage to only select the patients most need a cystoscopy. This, in turn, caused cancellation and postponements of many non-essential surgical procedures across the world.

<h3>Urinary Tract Cancer Treatment Market Segment Analysis</h3>

The bladder cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

According to cancer type, the bladder cancer segment dominated the market in 2020 and is expected to maintain this trend during the forecast period, owing to increases in healthcare expenditure, advancements in available therapies, and increased bladder cancer prevalence.

According to the Cancer.Net 2022, bladder cancer affects an estimated 81,180 persons in the United States (61,700 men and 19,480 women). Smoking is responsible for 47% of all instances . Bladder cancer affected an estimated 573,278 persons worldwide in 2020. This illness is expected to kill 17,100 people in the United States this year (12,120 males and 4,980 women). Bladder cancer claimed the lives of an estimated 212,536 persons worldwide in 2020. Bladder cancer is the eighth most common cause of cancer death in men in the United States. However, after decades with no meaningful change, the fatality rate for bladder cancer reduced by nearly 2% from 2015 to 2019. Bladder cancer primarily affects the elderly. Bladder cancer affects about 90% of adults over the age of 55. Bladder cancer strikes persons at an average age of 73. These factors will boost this segment.

Urinary Tract Cancer Treatment Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			18.4%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Cancer Type,&nbsp;By Treatment Type,&nbsp;By Distribution Channel,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

<h3>Urinary Tract Cancer Treatment Market Geographical Analysis</h3>

North America region holds the largest market share of the global urinary tract cancer treatment market

North America accounted for a large share of the urinary tract cancer market in 2020 and is expected to maintain its dominance during the forecast period because of the rising prevalence of bladder cancer, increased healthcare expenditure, the presence of key players, availability of advanced cancer therapy, and advancement in R&amp;D activities in the healthcare sector in the region

In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market. For instance, in August 2021, BAVENCIO has been approved by the Food and Drug Administration (FDA) as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma. Furthermore, advancements in various treatment for urinary tract cancer from established key players, in the United States, are likely to drive the market growth in North America.

<h3>Urinary Tract Cancer Treatment Market Competitive Landscape</h3>

The urinary tract cancer treatment market is a moderately competitive presence of local as well as global companies. &nbsp;Some of the key players which are contributing to the growth of the market include Astellas Pharma Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International Plc, Exelixis Inc, GlaxoSmith Plc, Merck KGaA, Novartis AG, Pfizer Inc, Johnson &amp; Johnson among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the urinary tract cancer treatment market globally. For instance, In September 2021, PADCEV&reg; (enfortumab vedotin) is approved by Japan&#39;s MHLW for advanced urothelial cancer.

Eli Lilly and Company

Overview: 

Eli Lilly and Corporation is an American pharmaceutical company with 18 countries and headquarters in Indianapolis, Indiana. Its goods are sold in more than 125 countries. Colonel Eli Lilly, a pharmaceutical chemist and American Civil War veteran, created the company in 1876 and named it after him.

Product Portfolio:

Cyramza: &nbsp;Cyramza (ramucirumab) is a single-agent recombinant human IgG1 monoclonal antibody intended to treat patients with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma who have progressed on or after fluoropyrimidine- or platinum-containing chemotherapy.

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Frequently Asked Questions</h3>

What is the Projected CAGR value of the Urinary Tract Cancer Treatment Market?

Urinary Tract Cancer Treatment Market is expected to grow at a&nbsp;CAGR of 18.4%&nbsp;during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America&nbsp;region Controls&nbsp;the&nbsp;Urinary Tract Cancer Treatment Market&nbsp;during 2022-2029

Which is the fastest growing region in the Urinary Tract Cancer Treatment Market?

Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period&nbsp;

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>Methodology and Scope

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet By Cancer Type</li>
		<li>Market snippet By Treatment Type</li>
		<li>Market Snippet By Distribution Channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing awareness about urinary tract cancer treatment</li>
				<li>Increasing healthcare expenditure.</li>
				<li>Increasing prevalence of bladder cancer.</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Side effects of medications.</li>
				<li>Rise in the number of patent expiration and increased use of generic drugs</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis
	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Regulatory Analysis</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>By Cancer Type
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type Segment</li>
			<li>Market Attractiveness Index, By Cancer Type Segment</li>
		</ol>
		</li>
		<li>Bladder Cancer*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Urethral Cancer</li>
		<li>Ureteric Cancer</li>
		<li>Renal Pelvic Cancer</li>
	</ol>
	</li>
	<li>By Treatment Type
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Attractiveness Index, By Treatment Type</li>
		</ol>
		</li>
		<li>Immunotherapy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Chemotherapy
		<ol>
			<li>Gemcitabine</li>
			<li>Cisplatin</li>
			<li>Docetaxel</li>
			<li>Paclitaxel</li>
			<li>Doxorubicin</li>
			<li>Methotrexate</li>
			<li>Ifosfamide</li>
			<li>Pemetrexed</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel Segment</li>
		</ol>
		</li>
		<li>Retail Pharmacy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Online Pharmacy</li>
		<li>Hospital Pharmacy</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment &nbsp;Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>The U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment &nbsp;Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>Eli Lilly and Company*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Bristol-Myers Squibb Company</li>
		<li>Astellas Pharma Inc</li>
		<li>EndoInternational plc</li>
		<li>Exelixis Inc</li>
		<li>GlaxoSmithKline Plc</li>
		<li>Merck KGaA</li>
		<li>Novartis AG</li>
		<li>Pfizer Inc</li>
		<li>Johnson &amp; Johnson(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>DataM Intelligence
	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 01Global Urinary Tract Cancer Treatment Market Value, By Cancer Type, 2021,2025 &amp; 2029($ Million)

Table 02Global Urinary Tract Cancer Treatment Market Value, By Treatment Type, 2021,2025 &amp; 2029($ Million)

Table 03Global Urinary Tract Cancer Treatment Market Value, By Cancer Type, 2021,2025 &amp; 2029($ Million)

Table 04Global Urinary Tract Cancer Treatment Market Value, By Cancer Type, 2020-2029($ Million)

Table 05Global Urinary Tract Cancer Treatment Market Value, By Treatment Type, 2021,2025 &amp; 2029($ Million)

Table 06Global Urinary Tract Cancer Treatment Market Value, By Treatment Type, 2020-2029($ Million)

Table 07North America Urinary Tract Cancer Treatment Market Value, By Cancer Type, 2020-2029($ Million)

Table 08North America Urinary Tract Cancer Treatment Market Value, By Treatment Type, 2020-2029($ Million)

Table 09North America Urinary Tract Cancer Treatment Market Value, By Distribution Channel, 2020-2029($ Million)

Table 10South America Urinary Tract Cancer Treatment Market Value, By Cancer Type, 2020-2029($ Million)

Table 11South America Urinary Tract Cancer Treatment Market Value, By Treatment Type, 2020-2029($ Million)

Table 12South America Urinary Tract Cancer Treatment Market Value, By Distribution Channel, 2020-2029($ Million)

Table 13Europe Urinary Tract Cancer Treatment Market Value, By Cancer Type, 2020-2029($ Million)

Table 14Europe Urinary Tract Cancer Treatment Market Value, By Treatment Type, 2020-2029($ Million)

Table 15Europe Urinary Tract Cancer Treatment Market Value, By Distribution Channel, 2020-2029($ Million)

Table 16Asia-Pacific Urinary Tract Cancer Treatment Market Value, By Cancer Type, 2020-2029($ Million)

Table 17Asia-Pacific Urinary Tract Cancer Treatment Market Value, By Treatment Type, 2020-2029($ Million)

Table 18Asia-Pacific Urinary Tract Cancer Treatment Market Value, By Distribution Channel, 2020-2029($ Million)

Table 19Middle East &amp; Africa Urinary Tract Cancer Treatment Market Value, By Cancer Type, 2020-2029($ Million)

Table 20Middle East &amp; Africa Urinary Tract Cancer Treatment Market Value, By Treatment Type, 2020-2029($ Million)

Table 21Astellas Pharma Inc: Overview

Table 22Astellas Pharma Inc: Product Portfolio

Table 23Astellas Pharma Inc: Key Developments

Table 24Bristol-Myers Squibb Company: Overview

Table 25Bristol-Myers Squibb Company: Product Portfolio

Table 26Bristol-Myers Squibb Company: Key Developments

Table 27Eli Lilly and Company: Overview

Table 28Eli Lilly and Company: Product Portfolio

Table 29Eli Lilly and Company: Key Developments

Table 30EndoInternational Plc: Overview

Table 31EndoInternational Plc: Product Portfolio

Table 32EndoInternational Plc: Key Developments

Table 33Exelixis Inc: Overview

Table 34Exelixis Inc: Product Portfolio

Table 35Exelixis Inc: Key Developments

Table 36GlaxoSmithKline Plc: Overview

Table 37GlaxoSmithKline Plc: Product Portfolio

Table 38GlaxoSmithKline Plc: Key Developments

Table 39Merck KGaA: Overview

Table 40Merck KGaA: Product Portfolio

Table 41Merck KGaA: Key Developments

Table 42Novartis AG: Overview

Table 43Novartis AG: Product Portfolio

Table 44Novartis AG: Key Developments

Table 45Pfizer Inc: Overview

Table 46Pfizer Inc: Product Portfolio

Table 47Pfizer Inc: Key Developments

Table 48Johnson &amp; Johnson: Overview

Table 49Johnson &amp; Johnson: Product Portfolio

Table 50Johnson &amp; Johnson: Key Developments&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

List of Figures

Figure 01Global Urinary Tract Cancer Treatment Market Share, By Cancer Type, 2020 &amp; 2029(%)

Figure 02Global Urinary Tract Cancer Treatment Market Share, By Treatment Type, 2020 &amp; 2029(%)

Figure 03Global Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 04Global Urinary Tract Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2020-2028 (%)

Figure 05Bladder Cancer: Global Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 06Urethral Cancer: Global Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 07Ureteric Cancer: Global Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 08Renal Pelvic Cancer: Global Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 09Global Urinary Tract Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2020-2028 (%)

Figure 10Chemotherapy: Global Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 11Immunotherapy: Global Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 12North America Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 13North America Urinary Tract Cancer Treatment Market Share, By Cancer Type, 2020 &amp; 2029(%)

Figure 14North America Urinary Tract Cancer Treatment Market Share, By Treatment Type, 2020 &amp; 2029(%)

Figure 15North America Urinary Tract Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029(%)

Figure 16South America Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 17South America Urinary Tract Cancer Treatment Market Share, By Cancer Type, 2020 &amp; 2029(%)

Figure 18South America Urinary Tract Cancer Treatment Market Share, By Treatment Type, 2020 &amp; 2029(%)

Figure 19South America Urinary Tract Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029(%)

Figure 20Europe Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 21Europe Urinary Tract Cancer Treatment Market Share, By Cancer Type, 2020 &amp; 2029(%)

Figure 22Europe Urinary Tract Cancer Treatment Market Share, By Treatment Type, 2020 &amp; 2029(%)

Figure 23Europe Urinary Tract Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029(%)

Figure 24Asia-Pacific Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 25Asia-Pacific Urinary Tract Cancer Treatment Market Share, By Cancer Type, 2020 &amp; 2029(%)

Figure 26Asia-Pacific Urinary Tract Cancer Treatment Market Share, By Treatment Type, 2020 &amp; 2029(%)

Figure 27Asia-Pacific Urinary Tract Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029(%)

Figure 28Middle East &amp; Africa Urinary Tract Cancer Treatment Market Value, 2020-2029($ Million)

Figure 29Middle East &amp; Africa Urinary Tract Cancer Treatment Market Share, By Cancer Type, 2020 &amp; 2029(%)

Figure 30Middle East &amp; Africa Urinary Tract Cancer Treatment Market Share, By Treatment Type, 2020 &amp; 2029(%)

Figure 31Astellas Pharma Inc: Financials

Figure 32Bristol-Myers Squibb Company: Financials

Figure 33Eli Lilly and Company: Financials

Figure 34EndoInternational Plc: Financials

Figure 35Exelixis Inc: Financials

Figure 36GlaxoSmithKline Plc: Financials

Figure 37Merck KGaA: Financials

Figure 38Novartis AG: Financials

Figure 39Pfizer Inc: Financials

Figure 40Johnson &amp; Johnson: Financials